INDIANAPOLIS, Nov. 20, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced that management will participate in upcoming investor conferences.
On Wednesday, December 3, Jeff Simmons, president and CEO, will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference at 12:30 p.m. ET.
On Thursday, December 4, Bob VanHimbergen, executive vice president and CFO, and Bobby Modi, executive vice president, US Pet Health and Global Digital Transformation, will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference at 8:30 a.m. ET.
Live audio webcasts will be available in the "Events and Presentations" section of Elanco's investor website. Replays will be available for a limited time at the conclusion of the event.
ABOUT ELANCO
Elanco Animal Health Incorporated (NYSE: ELAN) is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders and society as a whole. With 70 years of animal health heritage, we are committed to breaking boundaries and going beyond to help our customers improve the health of animals in their care, while also making a meaningful impact on our local and global communities. At Elanco, we are driven by our vision of Food and Companionship Enriching Life and our purpose – all to Go Beyond for Animals, Customers, Society and Our People. Learn more at www.elanco.com.
Investor Contact: Tiffany Kanaga (765) 740-0314 This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact: Colleen Parr Dekker (317) 989-7011 This email address is being protected from spambots. You need JavaScript enabled to view it.

| Last Trade: | US$22.25 |
| Daily Change: | 1.01 4.76 |
| Daily Volume: | 8,203,966 |
| Market Cap: | US$11.060B |
November 21, 2025 November 13, 2025 November 05, 2025 October 24, 2025 | |

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load